Month: February 2024

~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three...

Contacts Shane Kleinstein 720-875-5432 Qurate Retail, Inc. ("Qurate Retail") (Nasdaq: QRTEA, QRTEB, QRTEP) today reported fourth quarter and year end...

Contacts Shane Kleinstein 720-875-5432 Qurate Retail, Inc. ("Qurate Retail") (Nasdaq: QRTEA, QRTEB, QRTEP) today reported fourth quarter and year end...

Contacts Shane Kleinstein 720-875-5432 Qurate Retail, Inc. ("Qurate Retail") (Nasdaq: QRTEA, QRTEB, QRTEP) today reported fourth quarter and year end...

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming...

Third quarter reported net sales increased 1.0 percent year-over-year to $1.62 billion. Internal sales increased 0.3 percent year-over-year, driven by...

SAN DIEGO and CALGARY, AB, Feb. 28, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused...

Q4 Consolidated Net Revenue Drives Operating Income of $230 Million, Net Income of $100 Million, Consolidated Adjusted EBITDA of $411...

Full Year 2023 GAAP Revenue of $882 million Full Year 2023 GAAP Net Income of $73 million Full Year 2023...

TULSA, Okla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Matrix Service Company (Nasdaq: MTRX) announced today that President and Chief Executive Officer...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...

--Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)--...

Continues to Work Diligently Towards Regaining Compliance Contacts Investors: Jenny Gelinas 312-506-1237 jenny.gelinas@veradigm.com Media: Concetta Rasiarmos 312-447-2466 concetta.rasiarmos@veradigm.com Veradigm Inc....

CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for...

Contacts Investor and Media: Rob Windsor Rwindsor@serestherapeutics.com Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that...

Contacts Dan Galves Investor Relations investors@mobileye.com Justin Hyde Media Relations justin.hyde@mobileye.com Mobileye Global Inc. (Nasdaq: MBLY) (“Mobileye”) announced today that...

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...

PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced...

REHOVOT, Israel, and HOBOKEN, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage...

MCLEAN, Va., Feb. 28, 2024 /PRNewswire/ -- Iridium Communications Inc. (NASDAQ: IRDM), a leading provider of global voice and data satellite communications,...

CARLSBAD, Calif., Feb. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside...

Provides 2024 Financial Guidance and Updates Long-Term Targets Total Revenue of $97.8 million, down 10% Year-over-Year; Record Fourth Quarter Service...

June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS...

2023 Total Revenue of $399.4M, a 21% Increase Year-over-YearStrong Patient Demand Continues for Pombiliti™ + Opfolda™ in the U.S., U.K.,...

Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million Full Year 2023 Core Revenue...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...

Contacts Investor Relations Contact: Sara Sherman / Chinedu Okeke investors@exscientia.ai Media Contact: Oliver Stohlmann media@exscientia.ai Exscientia plc (Nasdaq: EXAI) today...

The payment completes the $5M advance payment received under the licensing agreement for bio-fungicide product candidates REHOVOT, Israel, Feb. 28,...

Company aligned with FDA that RUBY is a single Phase 1/2/3 trialOn track to present additional clinical data from the...

SHANGHAI, China, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility...

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- 1stdibs.com, Inc. (NASDAQ: DIBS), a leading online marketplace for luxury design products...

Full Year Net Sales Increased 15% to $494 million Driven by Vita Coco Coconut Water Growth of 14%Full Year Net...

ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and...

- Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating...

TORONTO and BROSSARD, Québec, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a global vertically integrated Bitcoin mining...

Contacts Investors: Stephanie Yao SVP, Investor Relations and Corporate Communications ir@bicycletx.com 857-523-8544 Media: Argot Partners Deborah Elson media@bicycletx.com 212-600-1902 Bicycle...

Achieved 39% profitability growth, net operating cash flow of $39 million and record Free Cash Flow in 2023 Expects 16%...

Fourth Quarter and Full Year 2023 Overview (all comparisons are made to the corresponding prior year fourth quarter or prior year,...

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today...

Alliance with one of Latin America’s leading providers of professional services for the payments industry will strengthen the adoption of...